Isolation of novel bacteriocins active against clinically relevant, pathogenic Clostridioides difficile

Abstract

The emergence of antibiotic resistant, hypervirulent strains of the nosocomial pathogen Clostridioides difficile, coupled with increased concerns over the physiological impact of traditional broad-spectrum antibiotics on human health has led to an increased demand for alternative therapies. Bacteriocins are proteinaceous toxins produced by bacteria that kill other bacteria and their antimicrobial activity makes them an attractive potential alternative therapy to antibiotics. This research aims to isolate environmental bacteria from porcine faeces that produce novel bacteriocins with inhibitory activity against C. difficile. At present in this study two distinct organisms with protein mediated inhibitory activity against C. difficile have been isolated and it has been shown that these strains encode various bacteriocins. The current focus of this research aims to attribute the inhibitory activity to one of the encoded bacteriocins or potentially a novel antimicrobial peptide, which could then be exploited as an alternative therapy against C. difficile.